Navigation Links
Global Antibacterial Drugs Market to 2022: Antibacterial Drug Market will Hit $35.6 Billion by 2022, as Efforts Increase to Tackle Antimicrobial Resistance - Research and Markets
Date:2/16/2017

DUBLIN, Feb 16, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance" report to their offering.

The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:

- How big is the antibiotic pipeline?

- How are companies attempting to overcome antibiotic resistance?

The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:

- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?

- Will vaccines continue to drive market revenue?

The pipeline contains a range of molecular targets:

- Which molecular targets are most popular in the current pipeline?

- How many late-stage products are active against drug-resistant bacteria?

- What are the commercial prospects for the most promising late-stage pipeline products?

Big Pharma maintains a strong presence within the antibacterial drug market:

- Which of the leading companies are expected to have the highest share of the market by 2022?

- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?

- Which companies rely heavily of revenues derived from antibacterial drugs?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Key Marketed Products

3.1 Overview

3.2 Cubicin (daptomycin) - Merck & Co

3.3 Augmentin - GlaxoSmithKline

3.4 Prevnar 13 - Pfizer

3.5 Infanrix - GlaxoSmithKline

3.6 Boostrix - GlaxoSmithKline

3.7 Zerbaxa - Merck and Co

3.8 Bexsero - GlaxoSmithKline

3.9 Zyvox - Pfizer

3.10 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Mechanisms of Action in Pipeline

4.4 Clinical Trial Landscape

4.5 Conclusion

4.6 Assessment of Key Pipeline Products

4.6.1 Solithera - Cempra

4.6.2 Arikace - Insmed

4.6.3 Cadazolid - Actelion

4.6.4 Plazomicin (plazomicin sulfate) - Achaogen

4.6.5 V114 - Merck & Co.

4.6.6 Suvratoxumab (MEDI4893) - MedImmune

4.6.7 Pf-06290510 (SA4Ag vaccine) - Pfizer

4.6.8 PF-06425090 - Pfizer

4.6.9 Conclusion

5 Multi-Scenario Market Forecast to 2022

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Mechanism of Action

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 Pfizer - Will it Maintain its Position as Market Leader?

6.1.2 GlaxoSmithKline - Will Revenues for Key Products Continue to Grow Over Forecast Period?

6.1.3 Merck & Co - How Will Key Approvals and Patent Expiries Affect Revenue?

6.1.4 Allergan - Revenues to Rise Rapidly Following Market Entry

6.1.5 Cempra - Set to Enter the Market in 2017

6.1.6 Insmed - Set to Enter the Market in 2018

6.1.7 Otsuka - How Will the Approval of Deltyba Affect Otsuka's Market Share?

6.1.8 Roche - Revenues to Continue to Decline Due to Lack of Pipeline Products

6.1.9 Bayer - Steady Decline as All Products Off-Patent

6.1.10 AstraZeneca - Set to Revitalize its Position within the Market

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.2 Co-development Deals

8 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/5x7jmj/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-antibacterial-drugs-market-to-2022-antibacterial-drug-market-will-hit-356-billion-by-2022-as-efforts-increase-to-tackle-antimicrobial-resistance---research-and-markets-300408724.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):